Background: To summarize the preliminary experience on Iressa for refractory non-small cell lung cancer (NSCLC).
Methods: Fifty-five patients with NSCLC, who failed after surgery, radiotherapy, chemotherapy or combination of the above modalities, were registered in this clinical trail. Prior to Iressa, 50 patients were in stage IV, and 5 in stage III. Iressa was administered orally at 250 mg, once a day until cancer progressed or severe toxicity occured, which made patients intolerable. The median time for administration of Iressa was 4 months.
Results: The toxicity of Iressa was tolerable with 47% of skin toxicity (rash) and 2%-7% of diarrhea, nausea, orally mucosal ulceration and alopecia. Overall response rate was 20%. Different sites of distant metastases responded to Iressa in different ways with higher response rate for pulmonary disseminations. One quarter of patients felt improvement of their symptoms over 2 weeks. Median survival time for entire group was 5 months (1-17 months). Median time to progression (TTP) was 3.6 months. Survival at 6 months was 67%. Prognostic predictor, which could imply the outcome, was skin toxicity with higher response rate and longer survival time ( P < 0.05), and no relationship with sex, histological types of NSCLC and distant metastasis had been found.
Conclusions: Iressa could be tolerated by refractory NSCLC patients with acceptable side-effects, and have palliative effects.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3779/j.issn.1009-3419.2004.04.08 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Enhanced brain tumor detection and segmentation using densely connected convolutional networks with stacking ensemble learning.
Comput Biol Med
January 2025
Emerging Technologies Research Lab (ETRL), College of Computer Science and Information Systems, Najran University, Najran, 61441, Saudi Arabia; Department of Computer Science, College of Computer Science and Information Systems, Najran University, Najran, 61441, Saudi Arabia. Electronic address:
- Brain tumors (BT), both benign and malignant, pose a substantial impact on human health and need precise and early detection for successful treatment. Analysing magnetic resonance imaging (MRI) image is a common method for BT diagnosis and segmentation, yet misdiagnoses yield effective medical responses, impacting patient survival rates. Recent technological advancements have popularized deep learning-based medical image analysis, leveraging transfer learning to reuse pre-trained models for various applications.
View Article and Find Full Text PDFSafety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA®), for the Prevention of Recurrent Clostridioides difficile Infection in Participants With Inflammatory Bowel Disease in PUNCH CD3-OLS.
Inflamm Bowel Dis
January 2025
Department of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Background: Fecal microbiota, live-jslm (RBL; REBYOTA®), is the first single-dose, broad consortia, microbiota-based live biotherapeutic approved by the US Food and Drug Administration to prevent recurrent Clostridioides difficile infection (rCDI) in adults following standard-of-care antimicrobials. Inflammatory bowel disease (IBD) is a common risk factor for rCDI, yet patients with IBD are often excluded from prospective trials. This subgroup analysis of PUNCH CD3-OLS (NCT03931941) evaluated the safety and efficacy of RBL in participants with rCDI and IBD.
View Article and Find Full Text PDFDecoupled responses of soil microbial diversity and ecosystem functions to successive degeneration processes in alpine pioneer community.
Sci China Life Sci
January 2025
CAS Key Laboratory for Plant Diversity and Biogeography of East Asia, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming, 650201, China.
Many alpine ecosystems are undergoing vegetation degradation because of global changes, which are affecting ecosystem functioning and biodiversity. The ecological consequences of alpine pioneer community degradation have been less studied than glacial retreat or meadow degradation in alpine ecosystems. We document the comprehensive responses of microbial community characteristics to degradation processes using field-based sampling, conduct soil microcosm experiments to simulate the effects of global change on microorganisms, and explore their relationships to ecosystem functioning across stages of alpine pioneer community degradation.
View Article and Find Full Text PDFThree-year treatment with anti-CGRP monoclonal antibodies modifies migraine course: the prospective, multicenter I-GRAINE study.
J Neurol
January 2025
Clinical and Molecular Epidemiology, IRCCS San Raffaele Roma, Rome, Italy.
Objectives: To determine whether extending anti-CGRP mAb treatment beyond 3 years influences migraine course, we analyzed migraine frequency during the first month of treatment discontinuation following three 12-month treatment cycles (Ts).
Methods: This multicenter, prospective, real-world study enrolled 212 patients with high-frequency episodic migraine (HFEM) or chronic migraine (CM) who completed three consecutive Ts of subcutaneous anti-CGRP mAbs. Discontinuation periods (D1, D2, D3) were defined as the first month after T1, T2, and T3, respectively.
Monocyte and Macrophage in Follicular Liquid: Predictive Markers of Embryo Quality in Women with Obesity and Infertility.
Front Biosci (Landmark Ed)
January 2025
Division of Biochemistry and Molecular Biology, Federal State Budgetary Educational Institution of Higher Education "Siberian State Medical University" of the Ministry of Health of Russia, 634050 Tomsk, Russia.
Background: Over the past five years, the pregnancy rate in assisted reproductive technology (ART) programs in Russia has remained relatively stable. The aim of this study was to assess the distribution of monocyte and macrophage subsets in the blood and follicular fluid of infertile women undergoing assisted reproductive technology.
Methods: The study involved 45 women with a mean age of 35 ± 4.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!